Cargando…

Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)

Purpose: Omidenepag isopropyl (OMDI) is a prodrug of OMD, a selective, nonprostaglandin, prostanoid EP2 receptor agonist. This phase I study aimed to investigate the pharmacokinetic properties, safety, and intraocular pressure (IOP)-lowering efficacy of OMDI. Methods: Fourteen healthy male volunteer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aihara, Makoto, Lu, Fenghe, Kawata, Hisashi, Tanaka, Yuki, Yamamura, Kenzo, Odani-Kawabata, Noriko, Shams, Naveed K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918846/ https://www.ncbi.nlm.nih.gov/pubmed/31674861 http://dx.doi.org/10.1089/jop.2019.0044

Ejemplares similares

A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
por: Olander, Kenneth W., et al.
Publicado: (2021)

The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice
por: Esaki, Yoshihiko, et al.
Publicado: (2020)

Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells
por: Yamamoto, Yasuko, et al.
Publicado: (2020)

Omidenepag, a Selective, Prostanoid EP2 Agonist, Does Not Suppress Adipogenesis in 3D Organoids of Human Orbital Fibroblasts
por: Hikage, Fumihito, et al.
Publicado: (2021)

Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells
por: Ida, Yosuke, et al.
Publicado: (2020)

Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension
por: Matsuo, Masato, et al.
Publicado: (2022)

Omidenepag Isopropyl in Latanoprost Low/Nonresponders With Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 3, Nonrandomized, Two-Phase, Open-Label Study
por: Panarelli, Joseph F., et al.
Publicado: (2023)

Reactivities of a Prostanoid EP2 Agonist, Omidenepag, Are Useful for Distinguishing between 3D Spheroids of Human Orbital Fibroblasts without or with Graves’ Orbitopathy
por: Ida, Yosuke, et al.
Publicado: (2021)

Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
por: Inoue, Kenji, et al.
Publicado: (2020)

Downregulation of COL12A1 and COL13A1 by a selective EP2 receptor agonist, omidenepag, in human trabecular meshwork cells
por: Kumon, Masashi, et al.
Publicado: (2023)

Twenty-Four-Hour Intraocular Pressure Control with Omidenepag Isopropyl 0.002% in Patients with Glaucoma and Ocular Hypertension
por: Shiratori, Naka, et al.
Publicado: (2021)

Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan
por: Nakazawa, Toru, et al.
Publicado: (2022)

Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study
por: Nakakura, Shunsuke, et al.
Publicado: (2021)

Evaluation of Patterns and Correlations of the Degree of Conjunctival Hyperemia Induced by Omidenepag Isopropyl 0.002% and Ripasudil 0.4%
por: Terao, Etsuko, et al.
Publicado: (2020)

Effects of selective EP2 receptor agonist, omidenepag, on trabecular meshwork cells, Schlemm’s canal endothelial cells and ciliary muscle contraction
por: Nakamura, Natsuko, et al.
Publicado: (2021)

Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan
por: Miki, Atsuya, et al.
Publicado: (2022)

Cystoid macular edema associated with omidenepag isopropyl in a phakic eye with an implantable collamer lens: a case report
por: Bae, Byung-Jin, et al.
Publicado: (2023)

Comparison of the Drug-Induced Efficacies between Omidenepag Isopropyl, an EP2 Agonist and PGF2α toward TGF-β2-Modulated Human Trabecular Meshwork (HTM) Cells
por: Suzuki, Soma, et al.
Publicado: (2022)

EP4-mediated prostanoid signalling promotes oral cancer progression
por: Sapienza, Karen, et al.
Publicado: (2010)

E-type prostanoid receptor 4 (EP4) in disease and therapy
por: Konya, Viktoria, et al.
Publicado: (2013)

Improved homology modeling of the human & rat EP(4) prostanoid receptors
por: Holt, Melissa C., et al.
Publicado: (2019)

Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4%
por: Terao, Etsuko, et al.
Publicado: (2020)

Laropiprant Attenuates EP3 and TP Prostanoid Receptor-Mediated Thrombus Formation
por: Philipose, Sonia, et al.
Publicado: (2012)

Laropiprant attenuates EP(3) and TP prostanoid receptor-mediated thrombus formation
por: Philipose, Sonia, et al.
Publicado: (2012)

One-Year Follow-Up Study of Changes in Prostaglandin-Associated Periorbital Syndrome After Switch From Conventional Prostaglandin F2alfa to Omidenepag Isopropyl
por: Oogi, Satomi, et al.
Publicado: (2020)

Saliva of the Lyme disease vector, Ixodes dammini, blocks cell activation by a nonprostaglandin E2-dependent mechanism
Publicado: (1994)

The Gαs‐protein‐mediated pathway may be steadily stimulated by prostanoid EP2 receptors, but not by EP4 receptors
por: Fukushima, Keijo, et al.
Publicado: (2022)

Expression of Prostanoid EP3 Receptors in Oral Squamous Epithelium and Oral Squamous Cell Carcinoma
por: Kashif, Muhammad, et al.
Publicado: (2015)

Contribution of prostanoid FP receptor and prostaglandins in transient inflammatory ocular hypertension
por: Yamagishi-Kimura, Reiko, et al.
Publicado: (2018)

Prostaglandin E(2) Prevents Hyperosmolar-Induced Human Mast Cell Activation through Prostanoid Receptors EP(2) and EP(4)
por: Torres-Atencio, Ivonne, et al.
Publicado: (2014)

Detrimental role of the EP1 prostanoid receptor in blood-brain barrier damage following experimental ischemic stroke
por: Frankowski, Jan C., et al.
Publicado: (2015)

The affinity, intrinsic activity and selectivity of a structurally novel EP(2) receptor agonist at human prostanoid receptors
por: Coleman, R A, et al.
Publicado: (2019)

Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study
por: Wirta, David L., et al.
Publicado: (2022)

Physiology and pathophysiology of prostanoid receptors
por: Narumiya, Shuh
Publicado: (2007)

Expression of prostaglandin E(2) prostanoid receptor EP2 and interleukin-1β in laryngeal carcinoma – preliminary study
por: Mochocki, Marcin, et al.
Publicado: (2015)

Role of E-type prostaglandin receptor EP3 in the vasoconstrictor activity evoked by prostacyclin in thromboxane-prostanoid receptor deficient mice
por: Li, Zhenhua, et al.
Publicado: (2017)

Effect of Prostaglandin E2 Agonist Omidenepag on the Expression of Matrix Metalloproteinase in Trabecular Meshwork Cells
por: Kim, Jeong Yeub, et al.
Publicado: (2022)

Prostanoid Receptors in the Human Vascular Wall
por: Norel, Xavier
Publicado: (2007)

Prostanoid Metabolites as Biomarkers in Human Disease
por: Idborg, Helena, et al.
Publicado: (2022)

The Link between Prostanoids and Cardiovascular Diseases
por: Beccacece, Livia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j28ieckf241m4ckpbilv8d0bsf